2013年6大失败交易盘点

    Prosena公司

    • 交易：Prosena公司不等美国食品及药物管理局检验结果出炉就匆忙首发上市

    今年是公司上市的好年份，但也有失败个案。荷兰生物公司Prosensa公司6月上市首次募股，筹得8000万美元。这家公司主打产品是治疗肌肉营养不良的药品，它上市第一个月股价就上涨了154%。9月中旬，美国食品及药物管理局称，晚期测试显示，治疗肌肉营养不良的drisapersen并不具备明显优于安慰剂的疗效。结果，Prosensa公司股价一天狂泻70%。股价现处4.86美元，远低于13美元的上市价。

    Prosena

    • Deal: Prosena IPOs right before FDA results

    It was generally a good year for IPOs, but it was not without duds. Dutch biotech company Prosensa (RNA) raised $80 million in a June IPO. Its shares soared 154% in the first month of trading, despite the fact that most of the company's prospects were based on one muscular dystrophy drug. In mid-September, the FDA said that a late stage trial had revealed that the drug, drisapersen, was not significantly better than a placebo. Prosensa's stock plunged 70% in one day. It now trades for $4.86, far below its IPO price of $13.